source
- Latus Bio secures $42 million to launch Huntington’s disease gene therapy trialBiotech startup Latus Bio announced it has raised $42 million to fund its first clinical trials, including a gene‑therapy program aimed at Huntington’s disease. The capital will be used to seek FDA…
- Vertex halts mRNA cystic fibrosis program citing tolerability concernsVertex Pharmaceuticals announced it is ending development of its mRNA-based cystic fibrosis therapy after encountering tolerability problems that echo challenges seen elsewhere in the field. The B…